New Blood Cancer Treatment out of Israel may Kill Solid Tumors, According to a New Study

Oct 7, 2019 | Cancer, CAR T cell therapy, Immunotherapy, Oncology, Solid Tumors

Cancer Treatment Centers of America Investigators Dose First Patient in Experimental Immuno-Oncology Clinical Trial

Dr. Yaron Carmi with Tel Aviv University led this study of a revolutionary CAR-T cancer treatment, which has shown success in testing against the blood cancer leukemia. Now, based on this study, it appears that it could also work against solid tumor cells coated in specific antibodies.

Published in the Journal of Clinical Investigation, the study out of Tel Aviv University that chemotherapy is currently the most common treatment against fast-growing solid tumors. One challenge, however, is that chemotherapy attacks healthy cells and tumors at the same time, leading to serious side effects.

CAR T-Cell Therapy

Tel Aviv University explains that CAR T-cell therapy is a form of immunotherapy utilizing white blood cells, that play a central role in the immune response. With immunotherapy, T cells from the patient are collected and modified in the lab so that the team can produce “CARs” on their surface. These Chimeric Antigen Receptors allow the T cells to attach to specific antigen on the tumor cells and then kill them.

Why doesn’t CAR T-Cell Therapy Work on Solid Tumors?

Although engineered T cells have shown success in addressing blood cancer, use in solid cancers have been disappointing.

Lead Research/Investigator

Dr. Yaron Carmi,Tel Aviv University

Call to Action: Want to learn more and connect with Dr. Carmi?  Keep TrialSite News updated, and we can broker an introduction.


Pin It on Pinterest